CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc.

1:16-cv-00648

Overview

Case Number 1:16-cv-00648
Filing Date 2016-07-29
Status Terminated
Termination Date 2017-11-27
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:0145
Jury Demand None

Parties

Defendant

Teva Pharmaceuticals Industries Ltd. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

5 Attorneys Listed

Mark D. Schuman

UNDELIVERABLE EMAIL 8/30/2019

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Alexandra J. Olson

Email: aolson@carlsoncaspers.com

Samuel T. Lockner

Email: SLockner@carlsoncaspers.com

John W. Shaw

Shaw Keller LLP

Tel: +1 (302) 298-0701

I.M. Pei Building, 1105 North Market Street

Novartis AG Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Corporation Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

6 Attorneys Listed

Caitlin R. Looby

Email: caitlin.looby@wilmerhale.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Lisa J. Pirozzolo

Email: lisa.pirozzolo@wilmerhale.com

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Jeffrey S. Olshan

Email: jeff.olshan@wilmerhale.com

Plaintiff

Novartis Pharma AG Operating Company

Represented By

3 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 2 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (2 found):
U.S. Courts: 2
U.S. District Court 2014-06-25
1:14-cv-00820

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-03-21
1:12-cv-00366

Novartis Pharmaceuticals Corporation v. Actavis Inc

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6465504
Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
Filed: 2000-10-30
Issued: 2002-10-15
Expired (Term Ended)
Expires: 2019-04-05

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

2

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Claim Construction / Markman Filing 1 Procedural / Extension Motion 1

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME - filed by Novartis AG, Novartis Corporation, Novartis Pharma AG, Novartis Pharmaceuticals Corporation. (Smyth, Benjamin) Modified on...
Entry #27 • 2016-11-17 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 4/27/2017. Amended Pleadings due by 4/27/201...
Entry #19 • 2016-09-12 Document →

Docket Entries

(50 total)
Pleading / Complaint

COMPLAINT for PATENT INFRINGEMENT filed against Teva Pharmaceuticals Industries Ltd., Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1971540.) - filed by Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis Corporation. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(nmb) (Entered: 07/29/2016)

Entry #1 • 2016-07-29
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmb) (Entered: 07/29/2016)

Entry #2 • 2016-07-29
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 6/16/2016. Date of Expiration of Patent: 4/5/2016.Thirty Month Stay Deadline: 12/17/2018. (nmb) (Entered: 07/29/2016)

Entry #3 • 2016-07-29
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,465,504. (nmb) (Entered: 07/29/2016)

Entry #4 • 2016-07-29
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (nmb) (Entered: 07/29/2016)

Entry #5 • 2016-07-29
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc